A method of treating preventing or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T lymphocyte associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin such as abatacept.